AB — AB Science SA Share News
0.000.00%
Last trade - 00:00- €65.08m
- €73.85m
- €1.17m
Brief: AB Science Granted Authorization To Initiate Study Of AB8939
Brief: AB Science Gets FDA Authorization To Start Clinical Development Program Of Masitinib
Brief: AB Science End-June Cash Position Of EUR 17.7 Million
Brief: AB Science Receives Regulatory Authorization To Commence Second Phase 2 Covid-19 Study
Brief: AB Science Receives Health Canada Approval Letter To Commence Phase I/II Trial Of AB8939
Brief: AB Science Authorised To Resume Enrollment In Masitinib Study
Brief: AB Science Receives New Authorisations For masitinib Study
Brief: AB Science Announces Results From Masitinib Study Ab12003 In Prostate Cancer
Brief: AB Science To Present Latest Clinical Data On ALS At 2021 Symposium
Brief: AB Science Receives Second Authorisation To Resume Enrollment In Phase 3 Study Of Masitinib in Mastocytosis
Brief: AB Science Received First Authorization To Resume Patient Enrollment In Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis (ALS)
Brief: AB Science Announces Promising Results Of Phase 3 Study Of Alzheimer-Treating Drug
Brief: AB Science Announces Success Of Phase 3 AB09004 Study
Brief: AB Science: Publication In Science Confirms Potential Of Masitinib As Treatment Of COVID-19
Brief: AB Science Says Masitinib Extended Survival In Als By 25 Months Relative To Placebo
French and Benelux stocks-Factors to watch
Brief: AB Science: strategy to increase the value of masitinib and to consider NASDAQ listing
Brief: AB Science: Results From masitinib Study In Pancreatic Cancer
Brief: AB Science Announces A Voluntary Hold In The Clinical Studies Of Masitinib Worldwide